Percutaneous Radiofrequency Ablation for Trigeminal Neuralgia Management: A Randomized, Double-Blinded, Sham-Controlled Clinical Trial
Pain Medicine · 01.03.2023 · 24 (3) · 234-243
DOI: 10.1093/pm/pnac132 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, online erschienen am 27.08.2022. Verfasst von André Marques Mansano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesiology Department, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Trigeminal Neuralgia, Radiofrequency Ablation, Pulsed Radiofrequency Treatment. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Trigeminal neuralgia, considered by many the worst pain that humankind can experience, has been called “the suicide disease.” Neuroablative procedures are good options when conservative treatment fails to promote pain relief or in those whose side effects are unbearable. The objective was to compare the effectiveness and safety of trigeminal percutaneous radiofrequency ablation in classical refractory trigeminal neuralgia in a prospective, randomized, double-blind, sham-controlled clinical trial. We included 30 consecutive patients with classical trigeminal neuralgia who had failed to respond to drug treatment. The patients were randomly assigned into two groups: a thermal radiofrequency and a sham group. The thermal radiofrequency group were submitted to a 75°C lesion for 60 seconds after proper sensory and motor stimulation. All steps were carried out in the sham group except the thermal lesion. Patients were evaluated using the Numerical Rating Scale (NRS), the 36-Item Short-Form Health Survey questionnaire, and anticonvulsant dose. After 1 month, the mean NRS score decreased from 9.2 to 0.7 in the radiofrequency group and from 8.9 to 5.8 in the sham group. This significant reduction was measurable starting at day one after the procedure and remained significant throughout the first month. Changing groups was allowed after one month, after which the pain reduction was similar between the two groups. Percutaneous trigeminal radiofrequency ablation results in statistically and clinically significant greater pain relief than the sham procedure after 1 month of follow-up. These results support using radiofrequency nerve ablation as a treatment for refractory trigeminal neuralgia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Anesthesiology Department, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
- Interventional Pain Management, Hospita Israelita Albert Einstein, São Paulo, SP, Brazil.
- Pontifícia Universidade Católica de Campinas, São Paulo, SP, Brazil.
ORCID-Profile: André Marques Mansano
Zitieren
APA
Mansano, A. M., Frederico, T. N., Valentin, R. E. B., Carmona, M. J. C., & Ashmawi, H. A. (2023). Percutaneous Radiofrequency Ablation for Trigeminal Neuralgia Management: A Randomized, Double-Blinded, Sham-Controlled Clinical Trial. Pain Medicine, 24(3), 234-243. https://doi.org/10.1093/pm/pnac132
Vancouver
Mansano AM, Frederico TN, Valentin REB, Carmona MJC, Ashmawi HA. Percutaneous Radiofrequency Ablation for Trigeminal Neuralgia Management: A Randomized, Double-Blinded, Sham-Controlled Clinical Trial. Pain Medicine. 2023;24(3):234-243. doi:10.1093/pm/pnac132
BibTeX
@article{Mansano2023,
author = {Mansano, André Marques and Frederico, Thiago Nouer and Valentin, Raquel Elisa B and Carmona, Maria Jose Carvalho and Ashmawi, Hazem Adel},
title = {Percutaneous Radiofrequency Ablation for Trigeminal Neuralgia Management: A Randomized, Double-Blinded, Sham-Controlled Clinical Trial},
journal = {Pain Medicine},
year = {2023},
volume = {24},
number = {3},
pages = {234--243},
doi = {10.1093/pm/pnac132}
}
EUVIMED